Log In
Print
BCIQ
Print
Print this Print this
 

VB-111

  Manage Alerts
Collapse Summary General Information
Company VBL Therapeutics Ltd.
DescriptionNon-replicating adenovector, a modified murine pre-proendothelin promoter (PPE-1-3x) and a Fas-Chimera transgene to angiogenic tumor blood vessels developed using Vascular Targeting System (VTS) technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today